Ovid Therapeutics (OVID) Other Accumulated Expenses (2016 - 2022)

Ovid Therapeutics (OVID) has reported Other Accumulated Expenses for 7 consecutive years, with $139167.0 the latest figure, recorded in Q1 2022.

• For the quarter ending Q1 2022, Other Accumulated Expenses fell 79.33% year-over-year to $139167.0; the trailing twelve-month figure through Mar 2022 stood at $139167.0 (down 79.33% YoY), and the FY2021 full-year result was $546464.0, up 230.12% from the prior year.
• Other Accumulated Expenses retreated to $139167.0 in Q1 2022 per OVID's latest filing, from $546464.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.0 million in Q2 2021 and bottomed at $119940.0 in Q3 2021.
• Historically, Other Accumulated Expenses has averaged $342914.5 across 5 years, with a median of $184923.0 in 2018.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses jumped 621.03% in 2021, then sank 79.33% in 2022.
• Over 5 years, Other Accumulated Expenses stood at $184923.0 in 2018, then rose by 25.51% to $232095.0 in 2019, then dropped by 28.68% to $165536.0 in 2020, then surged by 230.12% to $546464.0 in 2021, then sank by 74.53% to $139167.0 in 2022.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $139167.0, $546464.0, and $119940.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.